Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 21Uterine Cervical Neoplasms 15Esophageal Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Vaginal Neoplasms 2Rhabdomyosarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Uveal Melanoma 1Uterine Neoplasms 1Sarcoma 1Retinoblastoma 1Recurrent Head and Neck Carcinoma 1Prostatic Diseases 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1Locally Advanced Cervical Adenocarcinoma 1Gynecologic Cancer 1Esophageal Squamous Cell Carcinoma 1Endometrial Clear Cell Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cervical Adenocarcinoma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Brachytherapy × 1 year × Clear all
NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡